444 related articles for article (PubMed ID: 31787104)
21. A Selective Bottleneck Shapes the Evolutionary Mutant Spectra of Enterovirus A71 during Viral Dissemination in Humans.
Huang SW; Huang YH; Tsai HP; Kuo PH; Wang SM; Liu CC; Wang JR
J Virol; 2017 Dec; 91(23):. PubMed ID: 28931688
[TBL] [Abstract][Full Text] [Related]
22. Insights into innate and adaptive immune responses in vaccine development against EV-A71.
Lim HX; Poh CL
Ther Adv Vaccines Immunother; 2019; 7():2515135519888998. PubMed ID: 31799495
[TBL] [Abstract][Full Text] [Related]
23. Enterovirus A71: virulence, antigenicity, and genetic evolution over the years.
Huang SW; Cheng D; Wang JR
J Biomed Sci; 2019 Oct; 26(1):81. PubMed ID: 31630680
[TBL] [Abstract][Full Text] [Related]
24. RSAD2 and AIM2 Modulate Coxsackievirus A16 and Enterovirus A71 Replication in Neuronal Cells in Different Ways That May Be Associated with Their 5' Nontranslated Regions.
Yogarajah T; Ong KC; Perera D; Wong KT
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263272
[TBL] [Abstract][Full Text] [Related]
25. Enterovirus A71 and coxsackievirus A16 show different replication kinetics in human neuronal and non-neuronal cell lines.
Yogarajah T; Ong KC; Perera D; Wong KT
Arch Virol; 2017 Mar; 162(3):727-737. PubMed ID: 27878462
[TBL] [Abstract][Full Text] [Related]
26. Hand, foot and mouth disease and herpangina caused by enterovirus A71 infections: a review of enterovirus A71 molecular epidemiology, pathogenesis, and current vaccine development.
Chang YK; Chen KH; Chen KT
Rev Inst Med Trop Sao Paulo; 2018 Nov; 60():e70. PubMed ID: 30427405
[TBL] [Abstract][Full Text] [Related]
27. Human Enterovirus 71 Protein Displayed on the Surface of Saccharomyces cerevisiae as an Oral Vaccine.
Zhang C; Wang Y; Ma S; Li L; Chen L; Yan H; Peng T
Viral Immunol; 2016 Jun; 29(5):288-95. PubMed ID: 27259043
[TBL] [Abstract][Full Text] [Related]
28. Antivirals and vaccines for Enterovirus A71.
Lin JY; Kung YA; Shih SR
J Biomed Sci; 2019 Sep; 26(1):65. PubMed ID: 31481071
[TBL] [Abstract][Full Text] [Related]
29. The transfer and decay of maternal antibodies against enterovirus A71, and dynamics of antibodies due to later natural infections in Chinese infants: a longitudinal, paired mother-neonate cohort study.
Wei X; Yang J; Gao L; Wang L; Liao Q; Qiu Q; Luo K; Yu S; Zhou Y; Liu F; Chen Q; Zhang J; Dai B; Yang H; Zhou J; Xing W; Chen X; He M; Ren L; Guo J; Luo L; Wu P; Chen Z; van Doorn HR; Cauchemez S; Cowling BJ; Yu H
Lancet Infect Dis; 2021 Mar; 21(3):418-426. PubMed ID: 33031750
[TBL] [Abstract][Full Text] [Related]
30. Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology.
Yang YT; Chow YH; Hsiao KN; Hu KC; Chiang JR; Wu SC; Chong P; Liu CC
Antiviral Res; 2016 Aug; 132():225-32. PubMed ID: 27387826
[TBL] [Abstract][Full Text] [Related]
31. [Analysis on epidemiological characteristics of enterovirus 71 cases of hand-foot-mouth disease based on the active monitoring in Guangdong Province in 2011-2015].
Xie DS; He JF; Yang F; Li H; Kang M; Zhang M; Ye X; Tan XH; Ni XH; Hu L; Sun LM
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jul; 52(7):738-742. PubMed ID: 29996302
[No Abstract] [Full Text] [Related]
32. Adaptation and Virulence of Enterovirus-A71.
Kobayashi K; Koike S
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452525
[TBL] [Abstract][Full Text] [Related]
33. Hsc70 regulates the IRES activity and serves as an antiviral target of enterovirus A71 infection.
Dong Q; Men R; Dan X; Chen Y; Li H; Chen G; Zee B; Wang MHT; He ML
Antiviral Res; 2018 Feb; 150():39-46. PubMed ID: 29180285
[TBL] [Abstract][Full Text] [Related]
34. Advances in anti-EV-A71 drug development research.
Wang S; Pang Z; Fan H; Tong Y
J Adv Res; 2024 Feb; 56():137-156. PubMed ID: 37001813
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model.
Liou AT; Liao CC; Chou SF; Chang YS; Chang CS; Shih C
J Biomed Sci; 2019 Nov; 26(1):93. PubMed ID: 31711481
[TBL] [Abstract][Full Text] [Related]
36. TREM-1 activation is a potential key regulator in driving severe pathogenesis of enterovirus A71 infection.
Amrun SN; Tan JJL; Rickett NY; Cox JA; Lee B; Griffiths MJ; Solomon T; Perera D; Ooi MH; Hiscox JA; Ng LFP
Sci Rep; 2020 Mar; 10(1):3810. PubMed ID: 32123257
[TBL] [Abstract][Full Text] [Related]
37. Discovery of 14S-(2'-chloro-4'-nitrophenoxy)-8R/S,17-epoxy andrographolide as EV-A71 infection inhibitor.
Dai K; Tan JK; Qian W; Lee RCH; Hann Chu JJ; Zhou GC
Biochem Pharmacol; 2021 Dec; 194():114820. PubMed ID: 34748818
[TBL] [Abstract][Full Text] [Related]
38. Antiviral activity of SP81 peptide against Enterovirus A71 (EV-A71).
Abd-Aziz N; Lee MF; Ong SK; Poh CL
Virology; 2024 Jan; 589():109941. PubMed ID: 37984152
[TBL] [Abstract][Full Text] [Related]
39. Cordycepin Inhibits Enterovirus A71 Replication and Protects Host Cell from Virus-Induced Cytotoxicity through Adenosine Action Pathway.
Lee YP; Yu CK; Wong TW; Chen LC; Huang BM
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543718
[TBL] [Abstract][Full Text] [Related]
40. An auto-antibody identified from phenotypic directed screening platform shows host immunity against EV-A71 infection.
Cheng YW; Chuang YC; Huang SW; Liu CC; Wang JR
J Biomed Sci; 2022 Feb; 29(1):10. PubMed ID: 35130884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
